bioRxivMicrobiologyPreprint
Genome-wide analysis of PTR/POT transporters in Candida species and their functional characterization in the newly emerged pathogen Candida auris
R. Khatoon, S. Sharma, R. Prasad, A. M. Lynn, A. Prakash, A. Banerjee
Abstract
The PTR or proton-dependent oligopeptide transporter (POT) family exploits the inwardly directed proton motive force to facilitate the cellular uptake of di- and tripeptides. Interestingly, representatives from the family have shown efficacy in delivering peptide-based antifungal derivatives in certain Candida species. Given the increased incidences of fungal infections by Candida species and the associated escalating orders of resistance against frontline antifungals, peptide derivatives are attractive therapeutic options. In that direction, the identification and characterization of PTR transporters serve as an essential first step in the translation of peptide-based antifungals as next-gen therapeutics. Herein, we present a genome-wide inventory of the PTR transporters in five prominent Candida species. Our study identifies 2 PTR transporters each in C. albicans and C. dubliniensis, 1 in C. glabrata, 4 in C. parapsilosis, and 3 in C. auris. Notably, despite all representatives retaining the conserved features seen in the PTR family, there exist two distinct classes of PTR transporters that differ in terms of their sequence identities and membrane topology. Further, we also evaluated the contribution of each PTR protein of the newly emerged multidrug-resistant C. auris in di-/tripeptide uptake. Notably, deletion of the PTR transporters encoded by BNJ08_003830 and BNJ08_005124 led to a marked reduction in the transport capabilities of several tested di-/tripeptides. Besides, BNJ08_005124 deletion also resulted in increased resistance towards the peptide-nucleoside drug Nikkomycin Z, pointing towards its predominant role in the uptake mechanism. Altogether, the study provides an important template for future structure-function investigations of PTR transporters in Candida species.
- organism: C. elegans
- assay: DNA methylation
- assay: whole-genome sequencing
- research focus: cell type annotation
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs
Johanna L. Rhodes, Jonathan L. Jacobs, … Vishnu P. Chaturvedi·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 19, 2024
- An atypical ABC transporter is involved in antifungal resistance and host interactions in the pathogenic fungus Cryptococcus neoformans
C. J. Winski, Y. Qian, … F. H. Santiago-Tirado·bioRxiv·Mar 28, 2022
- Broad sensitivity of Candida auris strains to quinolones and mechanisms of resistance
M. B. Lohse, M. T. Laurie, … A. D. Johnson·bioRxiv·Feb 16, 2023
- Genomic landscape of the DHA1 family in the newly emerged pathogen Candida auris and mapping substrate repertoire of the prominent member CauMdr1
R. Khatoon, S. Sharma, … A. Banerjee·bioRxiv·Mar 9, 2022
- Construction of a drug sensitised Candida auris strain
Mahnoor Hassan, Jessica Furner-Pardoe, … Barry Panaretou·bioRxiv·Dec 28, 2024
- Resistance to the antifungal activity of Aprotinin occurs through mutations in genes that function in cation homeostasis
A. I. McColl, R. Lowe, … M. Bleackley·bioRxiv·Jun 22, 2020